A clinical case of drug hypersensitivity syndrome with phenobarbital administration: drug-induced rash with eosinophilia and systemic symptoms or lupus-like syndrome?

Sirs,

On April 26, 2005, an 84-year-old woman was admitted to our department for syncope. She presented motor aphasia, nuchal rigidity and right hemiparesis. The remaining clinical examination was normal. Brain CT scan evidenced subarachnoid haemorrhagic effusion at the superior cistern, cisterna laminae terminalis and subarachnoid spaces of the left parietal convexity. During the CT exam, she presented a short-term tonic clonic episode, which cleared up spontaneously. Electroencephalography showed diffuse slowing of brain waves. She was treated with nimodipine i.v. and phenobarbital (100mg/day) by oral route: a gradual, clinical improvement, confirmed by brain CT scan, was evidenced. On May 9, she presented continuous, high fever, facial oedema and generalized morbilliform eruption, with puriginous papules and macules coalescing into larger patches. Laboratory tests revealed anaemia (10.9 g/dl), cosinophilia (15.1 %), an increase of ESR (35mm/first hour) and transaminases (SGOT 56 UI/l, n.v.=5-40). An abdomen echography showed mild dilatation of the gall bladder and was treated with heparin infusion. On May 11, she presented pulmonary effusion at the superior cistern, cisterna magna and generalized morbilliform eruption, with puriginous papules and macules coalescing into larger patches. Laboratory tests showed: antinuclear autoantibodies (ANAs) (fine speckled nuclear pattern 1:160, nuclear dots 1:640), Ro/SS-A and Ro/SS-B, screening-lupus anticoagulant (LA), IgA and IgM aCL (respectively, 12.1 APLU/ml, n.v.<10.0; 11.0 MPLU/ml, n.v.< 10.0) positive; immunoglobulins, C3 and C4, total B and T lymphocytes, CD4+ and CD8+ lymphocytes, anti-ds DNA, anti-Sm and anti-histone antibodies in normal limits or negative. The patient’s HLA haplotype was the following: A2-A3/B51-B52/ BW4/CW4-CW6/DR8/DQ4. On May 14, methylprednisolone treatment (40 mg/day) was started. Fever decreased rapidly and the rash disappeared completely one month later. On June 22, she was discharged from hospital in good health and did not present any subsequent recurrence. Our patient satisfies the diagnostic criteria for Drug-induced Rash with Eosinophilia and Systemic Symptoms (DRESS Syndrome), a severe, unexpected reaction to a medicine, starting one to eight weeks after taking the drug and affecting several organ systems contemporaneously (1). The pathogenesis is still unknown: Defects in drug metabolism, and/or a co-infection with HHV-6 (2) are the most quoted hypotheses. Phenobarbital can induce DRESS syndrome (3), not safely Drug-Induced Lupus Erythematosus (DILE) (4). Nevertheless, DILE (1) shares many clinical and laboratory findings with DRESS syndrome (5): a systemic involvement is always present; the disease starts after using the culprit drug; the clinical improvement begins when the drug is discontinued; serum immunological abnormalities are present. Moreover, DILE can be caused by anticonvulsants, except phenobarbital (6): But phenobarbital can induce ANAs positivity (7). At last, some immunological changes were demonstrated in DRESS syndrome: immunoglobulins were normal or increased; complement normal or decreased; ANAs, ENAs and antiphospholipid antibodies present or not (8, 9). Therefore, we asked ourselves: Are DRESS syndrome and DILE really different disorders? Might be they different patterns of the same immunological-mediated systemic drug reaction? How much might genetic assessment and/or environmental factors influence the phenotypic expression of the disorders? The question remains: HLA DR4 predisposes to DILE (5), while there are no data on HLA antigens in DRESS syndrome; HHV-6 can be implicated in the pathogenesis of DRESS syndrome (2) and perhaps of SLE (10). Our patient did not present HLA DR4 and was negative for HHV-6: May these conditions justify the development of DRESS syndrome rather then DILE? This clinical case offers itself as an occasion for debate.

N. GIORDANO, MD, Associate Prof.
A. AMENDOLA, MD, Assistant Prof.
P. PAPAKOSTAS, MD, Assistant Prof.
F. CIPOLLI, MD, Assistant Prof.
F. FANTONI, MD, Associate Professor.
G. MARTINI, MD, Associate Professor.
G. CIACCI, Assistant Prof.
R. NUTI, MD, Professor

Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry and 1Department of Neurological Sciences of the University of Siena, Italy.

Please address correspondence to: Nicola Giordano, Policlinico Le Scotte, Viale Bracci 1, 53100, Siena, Italy.
E-mail: giordanoni@unisi.it

References